

JUN 24 2000

Berlex Laboratories, Inc.  
Attention: Ms. Marcia C. Garrigan  
340 Changebridge Road  
P.O. Box 1000  
Montville, NJ 07450-1000

Dear Ms. Garrigan:

Please refer to your supplemental new drug application dated November 16, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Quinaglute Dura-Tabs, 324 mg.

We acknowledge receipt of your submission dated May 25, 2000 that constituted a complete response to our April 20, 1999 approvable letter.

This supplemental new drug application provides for final printed labeling revised as follows:

1. Under CLINICAL PHARMACOLOGY/Pharmacokinetics and Metabolism, the following sentence has been added at the end of the first paragraph:

The rate of absorption of quinidine following the ingestion of grapefruit juice may be decreased.

2. The heading of the **PRECAUTIONS/Drug Interactions** subsection has been changed to **PRECAUTIONS/Drug and Diet Interactions**. This subsection has been revised as follows:

- a. Under *Altered pharmacokinetics of quinidine*, the following two paragraphs have been added to the end of this subsection:

***Grapefruit juice:*** Grapefruit juice inhibits P450 3A4-mediated metabolism of quinidine to 3-hydroxyquinidine. Although the clinical significance of this interaction is unknown, grapefruit juice should be avoided.

***Dietary salt:*** The rate and extent of quinidine absorption may be affected by changes in dietary salt intake; a decrease in dietary salt intake may lead to an increase in plasma quinidine concentrations.

- b. Under *Altered pharmacodynamics of other drugs*, the word diltiazem has been deleted from the first sentence of the last paragraph in the subsection. This sentence has been changed from:

Conversely, the pharmacokinetics of quinidine are not significantly affected by **caffeine, ciprofloxacin, digoxin, diltiazem, felodipine, omeprazole, or quinine.**

to:

Conversely, the pharmacokinetics of quinidine are not significantly affected by **caffeine, ciprofloxacin, digoxin, felodipine, omeprazole, or quinine.**

3. Under **OVERDOSAGE/Accelerated Removal**, the word “diltiazem” has been added to the fourth paragraph. This paragraph has been changed from:

Following quinidine overdose, drugs that delay elimination of quinidine (cimetidine, carbonic-anhydrase inhibitors, thiazide diuretics) should be withdrawn unless absolutely required.

to:

Following quinidine overdose, drugs that delay elimination of quinidine (cimetidine, carbonic-anhydrase inhibitors, diltiazem, thiazide diuretics) should be withdrawn unless absolutely required.

4. Under **HOW SUPPLIED**, the following changes were noted:

- a. The storage statement has been changed from:

Store tablets at controlled room temperature (15-30C; 59-86F).

to:

Store at 25C (77F); excursions permitted to 15-30C (59-86F).

[See USP Controlled Room Temperature.]


- b. The “Rx Only” statement has been deleted from this section and moved to above the **DESCRIPTION** section.

## QUINAGLUTE DURA-TABS® Tablets (brand of quinidine gluconate, extended-release tablets, USP)

R<sub>x</sub>Only

### DESCRIPTION:

Quinidine is an antimalarial schizonticide and an antiarrhythmic agent with Class Ia activity; it is the d-isomer of quinine, and its molecular weight is 324.43. Quinidine gluconate is the gluconate salt of quinidine; its chemical name is cinchonan-9-ol, 6'-methoxy-, (9S)-, mono-D-gluconate; its structural formula is:



Its empirical formula is  $C_{20}H_{24}N_2O_2 \cdot C_6H_{12}O_7$ , and its molecular weight is 520.58, of which 62.3% is quinidine base.

Each QUINAGLUTE DURA-TABS® tablet contains 324 mg of quinidine gluconate (202 mg of quinidine base) in a matrix to provide extended-release; the inactive ingredients include confectioner's sugar, magnesium stearate, corn starch and other ingredients. Meets USP Drug Release Test 4.

### CLINICAL PHARMACOLOGY

#### *Pharmacokinetics and Metabolism:*

The absolute **bioavailability** of quinidine from QUINAGLUTE® is 70- 80%. Relative to a solution of quinidine sulfate, the bioavailability of quinidine from QUINAGLUTE® is reported to be 1.03. The less-than-complete bioavailability is thought to be due to first-pass elimination by the liver. Peak serum levels generally appear 3-5 hours after dosing; when the drug is taken with food, absorption is increased in both rate (27%) and extent (17%). The rate and extent of absorption of quinidine from QUINAGLUTE® are not significantly affected by the coadministration of an aluminum-hydroxide antacid. The rate of absorption of quinidine following the ingestion of grapefruit juice may be decreased.

The **volume of distribution** of quinidine is 2-3 L/kg in healthy young adults, but this may be reduced to as little as 0.5 L/kg in patients with congestive heart failure, or increased to 3-5L/kg in patients with cirrhosis of the liver. At concentrations of 2-5 mg/L (6.5-16.2  $\mu$ mol/L), the fraction of quinidine bound to plasma proteins (mainly to  $\alpha_1$ -acid glycoprotein and to albumin) is 80-88% in adults and older children, but it is lower in pregnant women, and in infants and neonates it may be as low as 50-70%. Because  $\alpha_1$ -acid glycoprotein levels are increased in response to stress, serum levels of total quinidine may be greatly increased in settings such as acute myocardial infarction, even though the serum content of unbound (active) drug may remain normal. Protein binding is also increased in chronic renal failure, but binding abruptly descends toward or below normal when heparin is administered for hemodialysis.

Quinidine **clearance** typically proceeds at 3-5 mL/min/kg in adults, but clearance in children may be twice or three times as rapid. The elimination half-life is 6-8 hours in adults and 3-4 hours in children. Quinidine clearance is unaffected by hepatic cirrhosis, so the increased volume of distribution seen in cirrhosis leads to a proportionate increase in the elimination half-life.

Most quinidine is eliminated hepatically via the action of cytochrome P450III A4; there are several different hydroxylated metabolites, and some of these have antiarrhythmic activity.

The most important of quinidine's metabolites is 3-hydroxy-quinidine (3HQ), serum levels of which can approach those of quinidine in patients receiving conventional doses of QUINAGLUTE®. The volume of distribution of 3HQ appears to be larger than that of quinidine, and the elimination half-life of 3HQ is about 12 hours.

As measured by antiarrhythmic effects on animals, by QTc prolongation in human volunteers, or by various *in vitro* techniques, 3HQ has at least half the antiarrhythmic activity of the parent compound, so it may be responsible for a substantial fraction of the effect of QUINAGLUTE® in chronic use.

When the urine pH is less than 7, about 20% of administered quinidine appears unchanged in the urine, but this fraction drops to as little as 5% when the urine is more alkaline. Renal clearance involves both glomerular filtration and active tubular secretion, moderated by (pH-dependent) tubular reabsorption. The net renal clearance is about 1 mL/min/kg in healthy adults.

When renal function is taken into account, quinidine clearance is apparently independent of patient age.

**Assays** of serum quinidine levels are widely available, but the results of modern assays may not be consistent with results cited in the older medical literature. The serum levels of quinidine cited in this package insert are those derived from specific assays, using either

benzene extraction or (preferably) reverse-phase high-pressure liquid chromatography. In matched samples, older assays might unpredictably have given results that were as much as two or three times higher. A typical "therapeutic" concentration range is 2-6 mg/L (6.2-18.5 µmol/L).

### **Mechanisms of action**

In patients with malaria, quinidine acts primarily as an intra-erythrocytic schizonticide, with little effect upon sporozites or upon pre-erythrocytic parasites. Quinidine is gametocidal to *Plasmodium vivax* and *P. malariae*, but not to *P. falciparum*.

In cardiac muscle and in Purkinje fibers, quinidine depresses the rapid inward depolarizing sodium current, thereby slowing phase-0 depolarization and reducing the amplitude of the action potential without affecting the resting potential. In normal Purkinje fibers, it reduces the slope of phase-4 depolarization, shifting the threshold voltage upward toward zero. The result is slowed conduction and reduced automaticity in all parts of the heart, with increase of the effective refractory period relative to the duration of the action potential in the atria, ventricles, and Purkinje tissues. Quinidine also raises the fibrillation thresholds of the atria and ventricles, and it raises the ventricular defibrillation threshold as well. Quinidine's actions fall into Class Ia in the Vaughn-Williams classification.

By slowing conduction and prolonging the effective refractory period, quinidine can interrupt or prevent reentrant arrhythmias and arrhythmias due to increased automaticity, including atrial flutter, atrial fibrillation, and paroxysmal supraventricular tachycardia.

In patients with the sick sinus syndrome, quinidine can cause marked sinus node depression and bradycardia. In most patients, however, use of quinidine is associated with an increase in the sinus rate.

Like other antiarrhythmic drugs with Class Ia activity, quinidine prolongs the QT interval in a dose-related fashion. This may lead to increased ventricular automaticity and polymorphic ventricular tachycardias, including *torsades de pointes* (see **Warnings**).

In addition, quinidine has anticholinergic activity, it has negative inotropic activity, and it acts peripherally as an  $\alpha$ -adrenergic antagonist (that is, as a vasodilator).

### **Clinical effects**

**Maintenance of sinus rhythm after conversion from atrial fibrillation:** In six clinical trials (published between 1970 and 1984) with a total of 808 patients, quinidine (418 patients) was compared to nontreatment (258 patients) or placebo (132 patients) for the maintenance of sinus rhythm after cardioversion from chronic atrial fibrillation. Quinidine was consistently more efficacious in maintaining sinus rhythm, but a meta-analysis found that mortality in the quinidine-exposed patients (2.9%) was significantly greater than mortality in the patients who had not been treated with active drug (0.8%). Suppression of atrial fibrillation with quinidine has theoretical patient benefits (e.g., improved exercise tolerance; reduction in hospitalization for cardioversion; lack of arrhythmia-related palpitations, dyspnea and chest pain; reduced incidence of systemic embolism and/or stroke), but these benefits have never been demonstrated in clinical trials. Some of these benefits (e.g., reduction in stroke incidence) may be achievable by other means (anticoagulation).

By slowing the atrial rate in atrial flutter/fibrillation, quinidine can decrease the degree of atrioventricular block and cause an increase, sometimes marked, in the rate at which supraventricular impulses are successfully conducted by the atrioventricular node, with a resultant paradoxical increase in ventricular rate (see **Warnings**).

**Non-life-threatening ventricular arrhythmias:** In studies of patients with a variety of ventricular arrhythmias (mainly frequent ventricular premature beats and non-sustained ventricular tachycardia, quinidine (total n=502) has been compared with flecainide (n=141), mexiletine (n=246), propafenone (n=53), and tocainide (n=67). In each of these studies, the mortality in the quinidine group was numerically greater than the mortality in the comparator group. When the studies were combined in a meta-analysis, quinidine was associated with a statistically significant threefold relative risk of death.

At therapeutic doses, quinidine's only consistent effect upon the surface electrocardiogram is an increase in the QT interval. This prolongation can be monitored as a guide to safety, and it may provide better guidance than serum drug levels (see **Warnings**).

### **INDICATIONS AND USAGE**

**Conversion of atrial fibrillation/flutter:** In patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, QUINAGLUTE® is indicated as a means of restoring normal sinus rhythm. If this use of QUINAGLUTE® does not restore sinus rhythm within a reasonable time (see **Dosage and Administration**), then QUINAGLUTE® should be discontinued.

**Reduction of frequency of relapse into atrial fibrillation/flutter:** Chronic therapy with QUINAGLUTE® is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with QUINAGLUTE®. The increased risk of death should specifically be considered. QUINAGLUTE® should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate.

In patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. In most patients, the tachyarrhythmia *will recur* during therapy, and a single recurrence should not be interpreted as therapeutic failure.

**Suppression of ventricular arrhythmias:** QUINAGLUTE® is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. Where possible, therapy should be guided by the results of programmed electrical stimulation and/or Holter monitoring with exercise.

Antiarrhythmic drugs (including QUINAGLUTE®) have not been shown to enhance survival in patients with ventricular arrhythmias.

## CONTRAINDICATIONS

Quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine.

In the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block.

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent.

## WARNINGS

### *Mortality:*

**In many trials of antiarrhythmic therapy for non-life-threatening arrhythmias, active antiarrhythmic therapy has resulted in increased mortality; the risk of active therapy is probably greatest in patients with structural heart disease.**

**In the case of quinidine used to prevent or defer recurrence of atrial flutter/fibrillation, the best available data come from a meta-analysis described under Clinical Pharmacology/Clinical Effects above. In the patients studied in the trials there analyzed, the mortality associated with the use of quinidine was more than three times as great as the mortality associated with the use of placebo.**

**Another meta-analysis, also described under Clinical Pharmacology/Clinical Effects, showed that in patients with various non-life-threatening ventricular arrhythmias, the mortality associated with the use of quinidine was consistently greater than that associated with the use of any of a variety of alternative antiarrhythmics.**

**Proarrhythmic effects:** Like many other drugs (including all other Class Ia antiarrhythmics), quinidine prolongs the QTc interval, and this can lead to *torsades de pointes*, a life-threatening ventricular arrhythmia (see **Overdosage**). The risk of *torsades* is increased by bradycardia, hypokalemia, hypomagnesemia or high serum levels of quinidine, but it may appear in the absence of any of these risk factors. The best predictor of this arrhythmia appears to be the length of QTc interval, and quinidine should be used with extreme care in patients who have preexisting long-QT syndromes, who have histories of *torsades de pointes* of any cause, or who have previously responded to quinidine (or other drugs that prolong ventricular repolarization) with marked lengthening of the QTc interval. Estimation of the incidence of *torsades* in patients with therapeutic levels of quinidine is not possible from the available data.

Other ventricular arrhythmias that have been reported with quinidine include frequent extrasystoles, ventricular tachycardia, ventricular flutter, and ventricular fibrillation.

**Paradoxical increase in ventricular rate in atrial flutter/fibrillation:** When quinidine is administered to patients with atrial flutter/fibrillation, the desired pharmacologic reversion to sinus rhythm may (rarely) be preceded by a slowing of the atrial rate with a consequent increase in the rate of beats conducted to the ventricles. The resulting ventricular rate may be very high (greater than 200 beats per minute) and poorly tolerated. This hazard may be decreased if partial atrioventricular block is achieved prior to initiation of quinidine therapy, using conduction-reducing drugs such as digitalis, verapamil, diltiazem, or a  $\beta$ -receptor blocking agent.

**Exacerbated bradycardia in sick sinus syndrome:** In patients with the sick sinus syndrome, quinidine has been associated with marked sinus node depression and bradycardia.

**Pharmacokinetic considerations:** Renal or hepatic dysfunction causes the elimination of quinidine to be slowed, while congestive heart failure causes a reduction in quinidine's apparent volume of distribution. Any of these conditions can lead to quinidine toxicity if dosage is not appropriately reduced. In addition, interactions with coadministered drugs can alter the serum concentration and activity of quinidine, leading either to toxicity or to lack of efficacy if the dose of quinidine is not appropriately modified. (See **Precautions/Drug Interactions**.)

**Vagolysis:** Because quinidine opposes the atrial and A-V nodal effects of vagal stimulation, physical or pharmacological vagal maneuvers undertaken to terminate paroxysmal supraventricular tachycardia may be ineffective in patients receiving quinidine.

## PRECAUTIONS

### *Heart block*

In patients without implanted pacemakers who are at high risk of complete atrioventricular block (e.g., those with digitalis intoxication, second degree atrioventricular block, or severe intraventricular conduction defects), quinidine should be used only with caution.

### **Drug and Diet Interactions**

**Altered pharmacokinetics of quinidine:** diltiazem significantly decreases the clearance and increases the  $t_{1/2}$  of quinidine, but quinidine does not alter the kinetics of diltiazem.

Drugs that alkalinize the urine (**carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics**) reduce renal elimination of quinidine.

By pharmacokinetic mechanisms that are not well understood, quinidine levels are increased by coadministration of **amiodarone** or **cimetidine**. Very rarely, and again by mechanisms not understood, quinidine levels are decreased by coadministration of **nifedipine**.

Hepatic elimination of quinidine may be accelerated by coadministration of drugs (**phenobarbital**, **phenytoin**, **rifampin**) that induce production of cytochrome P450IIA4.

Perhaps because of competition for the P450IIA4 metabolic pathway, quinidine levels rise when **ketconazole** is coadministered.

Coadministration of **propranolol** usually does not affect quinidine pharmacokinetics, but in some studies the  $\beta$ -blocker appeared to cause increases in the peak serum levels of quinidine, decreases in quinidine's volume of distribution, and decreases in total quinidine clearance. The effects (if any) of coadministration of **other  $\beta$ -blockers** on quinidine pharmacokinetics have not been adequately studied.

Hepatic clearance of quinidine is significantly reduced during coadministration of **verapamil**, with corresponding increases in serum levels and half-life.

**Grapefruit juice:** Grapefruit juice inhibits P450 3A4-mediated metabolism of quinidine to 3-hydroxyquinidine. Although the clinical significance of this interaction is unknown, grapefruit juice should be avoided.

**Dietary salt:** The rate and extent of quinidine absorption may be affected by changes in dietary salt intake; a decrease in dietary salt intake may lead to an increase in plasma quinidine concentrations.

**Altered pharmacokinetics of other drugs:** Quinidine slows the elimination of **digoxin** and simultaneously reduces digoxin's apparent volume of distribution. As a result, serum digoxin levels may be as much as doubled. When quinidine and digoxin are coadministered, digoxin doses usually need to be reduced. Serum levels of **digitoxin** are also raised when quinidine is coadministered, although the effect appears to be smaller.

By a mechanism that is not understood, quinidine potentiates the anticoagulatory action of **warfarin**, and the anticoagulant dosage may need to be reduced.

Cytochrome P450IID6 is an enzyme critical to the metabolism of many drugs, notably including **mexiletine**, some **phenothiazines**, and most **polycyclic antidepressants**. Constitutional deficiency of cytochrome P450IID6 is found in less than 1% of Orientals, in about 2% of American blacks, and in about 8% of American whites. Testing with debrisoquine is sometimes used to distinguish the P450IID6-deficient "poor metabolizers" from the majority-phenotype "extensive metabolizers".

When drugs whose metabolism is P450IID6-dependent are given to poor metabolizers, the serum levels achieved are higher, sometimes much higher, than the serum levels achieved when identical doses are given to extensive metabolizers. To obtain similar clinical benefit without toxicity, doses given to poor metabolizers may need to be greatly reduced. In the case of prodrugs whose actions are actually mediated by P450IID6-produced metabolites (for example, **codeine** and **hydrocodone**, whose analgesic and antitussive effects appear to be mediated by morphine and hydromorphone, respectively), it may not be possible to achieve the desired clinical benefits in poor metabolizers.

Quinidine is not metabolized by cytochrome P450IID6, but therapeutic serum levels of quinidine inhibit the action of cytochrome P450IID6, effectively converting extensive metabolizers into poor metabolizers. Caution must be exercised whenever quinidine is prescribed together with drugs metabolized by cytochrome P450IID6.

Perhaps by competing for pathways of renal clearance, coadministration of quinidine causes an increase in serum levels of **procainamide**.

Serum levels of **haloperidol** are increased when quinidine is coadministered.

Presumably because both drugs are metabolized by cytochrome P450IIA4, coadministration of quinidine causes variable slowing of the metabolism of **nifedipine**. Interactions with other dihydropyridine calcium channel blockers have not been reported, but these agents (including **felodipine**, **nicardipine**, and **nimodipine**) are all dependent upon P450IIA4 for metabolism, so similar interactions with quinidine should be anticipated.

**Altered pharmacodynamics of other drugs:** Quinidine's anticholinergic, vasodilating, and negative inotropic actions may be additive to those of other drugs with these effects, and antagonistic to those of drugs with cholinergic, vasoconstricting, and positive inotropic effects. For example, when quinidine and **verapamil** are coadministered in doses that are each well tolerated as monotherapy, hypotension attributable to additive peripheral  $\alpha$ -blockade is sometimes reported.

Quinidine potentiates the actions of depolarizing (succinylcholine, decamethonium) and nondepolarizing (**d-tubocurarine**, **pancuronium**) **neuromuscular blocking agents**. These phenomena are not well understood, but they are observed in animal models as well as in humans. In addition, *in vitro* addition of quinidine to the serum of pregnant women reduces the activity of pseudocholinesterase, an enzyme that is essential to the metabolism of succinylcholine.

**Non-interactions of quinidine with other drugs:** Quinidine has no clinically significant effect on the pharmacokinetics of **diltiazem**, **flecainide**, **mephenytoin**, **metoprolol**, **propafenone**, **propranolol**, **quinine**, **timolol**, or **tocainide**.

Conversely, the pharmacokinetics of quinidine are not significantly affected by **caffeine**, **ciprofloxacin**, **digoxin**, **diltiazem**, **felodipine**, **omeprazole**, or **quinine**. Quinidine's pharmacokinetics are also unaffected by cigarette smoking.

## INFORMATION FOR PATIENTS

Before prescribing QUINAGLUTE® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected (see **Clinical Pharmacology**). Discussion should include the facts

- that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
- that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
- that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
- that such data as are available suggest that treatment with QUINAGLUTE® is likely to increase the patient's risk of death.

#### ***Carcinogenesis, mutagenesis, impairment of fertility***

Animal studies to evaluate quinidine's carcinogenic or mutagenic potential have not been performed. Similarly, there are no animal data as to quinidine's potential to impair fertility.

#### ***Pregnancy***

Pregnancy Category C. Animal reproductive studies have not been conducted with quinidine. There are no adequate and well-controlled studies in pregnant women. Quinidine should be given to a pregnant woman only if clearly needed.

In one neonate whose mother had received quinidine throughout her pregnancy, the serum level of quinidine was equal to that of the mother, with no apparent ill effect. The level of quinidine in amniotic fluid was about three times higher than that found in serum.

#### ***Labor and Delivery***

Quinine is said to be oxytocic in humans, but there are no adequate data as to quinidine's effects (if any) on human labor and delivery.

#### ***Nursing mothers***

Quinidine is present in human milk at levels slightly lower than those in maternal serum; a human infant ingesting such milk should (scaling directly by weight) be expected to develop serum quinidine levels at least an order of magnitude lower than those of the mother. On the other hand, the pharmacokinetics and pharmacodynamics of quinidine in human infants have not been adequately studied, and neonates' reduced protein binding of quinidine may increase their risk of toxicity at low total serum levels. Administration of quinidine should (if possible) be avoided in lactating women who continue to nurse.

#### ***Geriatric use***

Safety and efficacy of quinidine in elderly patients have not been systematically studied.

#### ***Pediatric use***

In antimalarial trials, quinidine was as safe and effective in pediatric patients as in adults. Notwithstanding the known pharmacokinetic differences between children and adults (see **Pharmacokinetics and Metabolism**), children in these trials received the same doses (on a mg/kg basis) as adults.

Safety and effectiveness of antiarrhythmic use in children have not been established.

### **ADVERSE REACTIONS**

Quinidine preparations have been used for many years, but there are only sparse data from which to estimate the incidence of various adverse reactions. The adverse reactions most frequently reported have consistently been gastrointestinal, including diarrhea, nausea, vomiting, and heartburn/esophagitis.

In the reported study that was closest in character to the predominant approved use of QUINAGLUTE®, 86 adult outpatients with atrial fibrillation were followed for six months while they received slow-release quinidine bisulfate tablets, 600 mg (approximately 400 mg of quinidine base) twice daily. The incidences of adverse experiences reported more than once were as shown in the table below. The most serious quinidine-associated adverse reactions are described above under **Warnings**.

#### **ADVERSE EXPERIENCES REPORTED MORE THAN ONCE IN 86 PATIENTS WITH ATRIAL FIBRILLATION**

	Incidence (%)	
Diarrhea	21	(24%)
fever	5	(6%)
rash	5	(6%)

arrhythmia	3	(3%)
abnormal electrocardiogram	3	(3%)
nausea/vomiting	3	(3%)
dizziness	3	(3%)
headache	3	(3%)
asthenia	2	(2%)
cerebral ischemia	2	(2%)

Vomiting and diarrhea can occur as isolated reactions to therapeutic levels of quinidine, but they may also be the first signs of **cinchonism**, a syndrome that may also include tinnitus, reversible high-frequency hearing loss, deafness, vertigo, blurred vision, diplopia, photophobia, headache, confusion, and delirium. Cinchonism is most often a sign of chronic quinidine toxicity, but it may appear in sensitive patients after a single moderate dose.

A few cases of **hepatotoxicity**, including granulomatous hepatitis, have been reported in patients receiving quinidine. All of these have appeared during the first few weeks of therapy, and most (not all) have remitted once quinidine was withdrawn.

**Autoimmune and inflammatory syndromes** associated with quinidine therapy have included fever, urticaria, flushing, exfoliative rash, bronchospasm, psoriasiform rash, pruritus and lymphadenopathy, hemolytic anemia, vasculitis, thrombocytopenic purpura, uveitis, angioedema, agranulocytosis, the sicca syndrome, arthralgia, myalgia, elevation in serum levels of skeletal-muscle enzymes, a disorder resembling systemic lupus erythematosus, and pneumonitis.

Convulsions, apprehension, and ataxia have been reported, but it is not clear that these were not simply the results of hypotension and consequent cerebral hypoperfusion. There are many reports of syncope. Acute psychotic reactions have been reported to follow the first dose of quinidine, but these reactions appear to be extremely rare.

Other adverse reactions occasionally reported include depression, mydriasis, disturbed color perception, night blindness, scotomata, optic neuritis, visual field loss, photosensitivity, and abnormalities of pigmentation.

## OVERDOSAGE

Overdoses with various oral formulations of quinidine have been well described. Death has been described after a 5-gram ingestion by a toddler, while an adolescent was reported to survive after ingesting 8 grams of quinidine.

The most important ill effects of acute quinidine overdoses are ventricular arrhythmias and hypotension. Other signs and symptoms of overdose may include vomiting, diarrhea, tinnitus, high-frequency hearing loss, vertigo, blurred vision, diplopia, photophobia, headache, confusion, and delirium.

**Arrhythmias:** Serum quinidine levels can be conveniently assayed and monitored, but the electrocardiographic QTc interval is a better predictor of quinidine-induced ventricular arrhythmias.

The necessary treatment of hemodynamically unstable polymorphic ventricular tachycardia (including *torsades de pointes*) is withdrawal of treatment with quinidine and either immediate cardioversion or, if a cardiac pacemaker is in place or immediately available, immediate overdrive pacing. After pacing or cardioversion, further management must be guided by the length of the QTc interval.

Quinidine-associated ventricular tachyarrhythmias with normal underlying QTc intervals have not been adequately studied. Because of the theoretical possibility of QT-prolonging effects that might be additive to those of quinidine, other antiarrhythmics with Class I (disopyramide, procainamide) or Class III activities should (if possible) be avoided. Similarly, although the use of bretylium in quinidine overdose has not been reported, it is reasonable to expect that the  $\alpha$ -blocking properties of bretylium might be additive to those of quinidine, resulting in problematic hypotension.

If the post-cardioversion QTc interval is prolonged, then the pre-cardioversion polymorphic ventricular tachycardia was (by definition) *torsades de pointes*. In this case, lidocaine and bretylium are unlikely to be of value, and other Class I antiarrhythmics (disopyramide, procainamide) are likely to exacerbate the situation. Factors contributing to QTc prolongation (especially hypokalemia and hypomagnesemia) should be sought out and (if possible) aggressively corrected. Prevention of recurrent *torsades* may require sustained overdrive pacing or the cautious administration of isoproterenol (30-150 ng/kg/min).



**Hypotension:** Quinidine-induced hypotension that is not due to an arrhythmia is likely to be a consequence of quinidine-related  $\alpha$ -blockade and vasorelaxation. Simple repletion of central volume (Trendelenburg positioning, saline infusion) may be sufficient therapy; other interventions reported to have been beneficial in this setting are those that increase peripheral vascular resistance, including  $\alpha$ -agonist catecholamines (norepinephrine, metaraminol) and the Military Anti-Shock Trousers.

#### **Treatment:**

To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison-Control Center. Telephone numbers of certified poison-control centers are listed in the Physicians' Desk Reference (PDR). In managing overdose, consider the possibilities of multiple-drug overdoses, drug-drug interactions, and unusual drug kinetics in your patient.

**Accelerated removal:** Adequate studies of orally-administered activated charcoal in human overdoses of quinidine have not been reported, but there are animal data showing significant enhancement of systemic elimination following this intervention, and there is at least one human case report in which the elimination half-life of quinidine in the serum was apparently shortened by repeated gastric lavage. Activated charcoal should be avoided if an ileus is present; the conventional dose is 1 gram/kg, administered every 2-6 hours as a slurry with 8 mL/kg of tap water.

Although renal elimination of quinidine might theoretically be accelerated by maneuvers to acidify the urine, such maneuvers are potentially hazardous and of no demonstrated benefit.

Quinidine is not usefully removed from the circulation by dialysis.

Following quinidine overdose, drugs that delay elimination of quinidine (cimetidine, carbonic-anhydrase inhibitors, diltiazem, thiazide diuretics) should be withdrawn unless absolutely required.

#### **DOSAGE AND ADMINISTRATION**

The dose of quinidine delivered by QUINAGLUTE DURA-TABS® tablets may be titrated by breaking a tablet in half. If tablets are crushed or chewed, their extended-release properties will be lost.

The dosage of quinidine varies considerably depending upon the general condition and the cardiovascular state of the patient.

#### **Conversion of atrial fibrillation/flutter to sinus rhythm**

Especially in patients with known structural heart disease or other risk factors for toxicity, initiation or dose-adjustment of treatment with QUINAGLUTE® should generally be performed in a setting where facilities and personnel for monitoring and resuscitation are continuously available. Patients with symptomatic atrial fibrillation/flutter should be treated with QUINAGLUTE® only after ventricular rate control (e.g., with digitalis or  $\beta$ -blockers) has failed to provide satisfactory control of symptoms.

Adequate trials have not identified an optimal regimen of QUINAGLUTE® for conversion of atrial fibrillation/flutter to sinus rhythm. In one reported regimen, the patient first receives two tablets (648 mg; 403 mg of quinidine base) of QUINAGLUTE® every eight hours. If this regimen has not resulted in conversion after 3 or 4 doses, then the dose is cautiously increased. If, at any point during administration, the QRS complex widens to 130% of its pre-treatment duration; the QTc interval widens to 130% of its pre-treatment duration and is then longer than 500 ms; P waves disappear; or the patient develops significant tachycardia, symptomatic bradycardia, or hypotension, then QUINAGLUTE® is discontinued, and other means of conversion (e.g., direct-current cardioversion) are considered.

In another regimen sometimes used, the patient receives one tablet (324 mg; 202 mg of quinidine base) every eight hours for two days; then two tablets every twelve hours for two days; and finally two tablets every eight hours for up to four days. The four-day stretch may come at one of the lower doses if, in the judgment of the physician, the lower dose is the highest one that will be tolerated. The criteria for discontinuation of treatment with QUINAGLUTE® are the same as in the other regimen.

#### **Reduction in the frequency of relapse into atrial fibrillation/flutter**

In a patient with a history of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy with QUINAGLUTE® should be an increase in the average time between episodes. In most patients, the tachyarrhythmia *will recur* during therapy with QUINAGLUTE®, and a single recurrence should not be interpreted as therapeutic failure.

Especially in patients with known structural heart disease or other risk factors for toxicity, initiation or dose-adjustment of treatment with QUINAGLUTE® should generally be performed in a setting where facilities and personnel for monitoring and resuscitation are continuously available. Monitoring should be continued for two or three days after initiation of the regimen on which the patient will be discharged.

Therapy with QUINAGLUTE® should be begun with one tablet (324 mg; 202 mg of quinidine base) every eight or twelve hours. If this regimen is well tolerated, if the serum quinidine level is still well within the laboratory's therapeutic range, and if the average time between arrhythmic episodes has not been satisfactorily increased, then the dose may be cautiously raised. The total daily dosage should be reduced if the QRS complex widens to 130% of its pre-treatment duration; the QTc interval widens to 130% of its pre-treatment duration and is then longer than 500 ms; P waves disappear; or the patient develops significant tachycardia, symptomatic bradycardia, or hypotension.

#### **Suppression of life-threatening ventricular arrhythmias**

Dosing regimens for the use of quinidine gluconate in suppressing life-threatening ventricular arrhythmias have not been adequately studied. Described regimens have generally been similar to the regimen described just above for the prophylaxis of symptomatic atrial fibrillation/flutter. Where possible, therapy should be guided by the results of programmed electrical stimulation and/or Holter monitoring.

with exercise.

#### HOW SUPPLIED

QUINAGLUTE DURA-TABS® tablets are 324 mg white to off-white, round tablets embossed with **C** in a flask design on one side and with a clock-like design on the other.



The tablets are available in bottles and unit-dose packages as follows:

bottle of 100	NDC 50419-101-10
---------------	------------------

bottle of 250	NDC 50419-101-25
---------------	------------------

bottle of 500	NDC 50419-101-50
---------------	------------------

unit-dose box of 100	NDC 50419-101-11
----------------------	------------------

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).  
[See USP Controlled Room Temperature.]

\*Tablet designs are registered trademarks of Berlex Laboratories

©1999, Berlex Laboratories. All rights reserved.

**BERLEX**® Laboratories, Wayne, NJ 07470

6069504 Rev. June 1999